Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the safety and efficacy of two doses of CNTX-6970 for the treatment of pain related to OA of the knee compared to placebo. CNTX-6970 is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.


Clinical Trial Description

The study will employ a randomized, allocation-concealed, multicenter, placebo-controlled, multi-period crossover design (Schmid et al, 2018). This multi-period crossover randomized, controlled trial allows comparability and assessment of efficacy through repeated exposures within each subject to the active treatment and a control (placebo) in randomized sequence. Such multi-period crossover designs are ideal for treatments with rapid onset of action and short half-life such as the asset under study here. We have strived to minimize the complexity of this powerful design by using only 2 blocks with 2 periods each. The modest additional complexity of the proposed multi-period crossover design, compared to a parallel-groups design, is justified by the marked improvement in efficiency. The gains in efficiency afforded by the multi-period crossover design allow a substantial reduction in sample size without sacrificing statistical power. For example, our simulation experiments (with sample sizes ranging from 30 to 50, carryover effects ranging from 0 to 0.2, and an effect size of 0.4) indicated that the parallel design yields statistical power ranging from 0.20-0.25, whereas our proposed 2-block multi-period crossover design yields power ranging from 0.9-1.0. The trial will compare an active treatment vs. placebo. Each arm of the study will employ a multi-period crossover design with two blocks. Each block will consist of two treatment periods with each period lasting 6 weeks. Treatment assignments (active drug versus placebo) will be randomized for each patient to the two periods within each block. The period length of 6 weeks was chosen based on several considerations: (i) Most efficacious analgesic drugs demonstrate separation from placebo by 6 weeks; (ii) The decision to move CNTX-6970 forward to Phase 3 will require a clinically meaningful separation from placebo by 6 weeks; (iii) In this Phase 2 study, implementing a treatment block longer than 6 weeks would make the overall design more challenging and burdensome by extending the duration of overall testing beyond 6 months; (iv) Recent meta-analyses suggest that anti-inflammatory treatments such as NSAIDs reach peak effects on pain within a 4-week timeframe in patients with knee osteoarthritis, and multiple RCTs have specifically demonstrated efficacy for celecoxib at 2-6 weeks (Osani et al, 2020). The comparison with celecoxib is used to evaluate "assay sensitivity," i.e., to assess the study protocol's ability to demonstrate superiority of an established efficacious treatment (celecoxib 100mg BID). In this study, the placebo will consist of inactive tablets identical to the active treatment tablets. Treatment assignments (active drug versus placebo) will be randomized for each patient to the two treatment periods within each block ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05025787
Study type Interventional
Source Massachusetts General Hospital
Contact Taylor O'Donnell, MSHA
Phone 781-956-9518
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date September 30, 2021
Completion date May 10, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04651673 - Prescribed Knee Brace Treatments for Osteoarthritis of the Knee (Knee OA)
Active, not recruiting NCT04043819 - Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis Phase 1
Recruiting NCT05014542 - Needling Techniques for Knee Osteoarthritis N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Completed NCT04779164 - The Relation Between Abdominal Obesity, Type 2 Diabetes Mellitus and Knee Osteoarthritis N/A
Recruiting NCT04006314 - Platelet Rich Plasma and Neural Prolotherapy Injections in Treating Knee Osteoarthritis N/A
Recruiting NCT04592562 - Genicular Artery Embolization to Reduce Pain Associated With Unilateral Mild to Moderate Osteoarthritis N/A
Enrolling by invitation NCT04145401 - Post Market Clinical Follow-Up Study- EVOLUTION® Revision CCK
Active, not recruiting NCT03781843 - Effects of Genicular Nerve Block in Knee Osteoarthritis N/A
Recruiting NCT04749628 - Cannabidiol for Bilateral Total Knee Arthroplasty Phase 4
Completed NCT04589858 - Effect of Manual Therapies With Supervised Exercise Protocol on Pain and Functional Disability in Patients With Knee OA N/A
Not yet recruiting NCT03825965 - Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT Phase 3
Not yet recruiting NCT04998188 - Hydrolyzed Collagen Formulation vs Placebo in Knee Osteoarthritis N/A
Not yet recruiting NCT04547595 - Hypnosis Intervention for the Management of Pain Perception During Joint Lavage Phase 3
Not yet recruiting NCT04885972 - Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis Phase 2
Not yet recruiting NCT04334278 - Development of a Mind Body Program for Obese Knee Osteoarthritis Patients With Comorbid Depression N/A
Not yet recruiting NCT04901273 - Homologous PRP vs Placebo in Knee Osteoarthritis in Over 65 Years Old Patients N/A
Not yet recruiting NCT04968132 - Opioid Reduction in Orthopaedic Surgery (OREOS) - Knees N/A
Not yet recruiting NCT04909099 - Arabic Version of the EARS Questionnaire
Not yet recruiting NCT04331990 - The Distraction of Knee Joint to Alleviate osteoArthritic Pain (DiKAP) Trial N/A